Impact Therapeutics licenses senaparib rights to Pharmanovia in Europe, Mideast, Africa, Australia, New Zealand for up to EUR 423.5 million

• Impact Therapeutics signed an exclusive license with Pharmanovia for senaparib across Europe, the Middle East and North Africa, Australia, New Zealand.
• Deal covers manufacturing, development, commercialization for maintenance monotherapy in advanced epithelial high-grade ovarian, fallopian tube, primary peritoneal cancer.
• Consideration totals up to EUR 423.5 million via upfront, regulatory milestones, sales-based milestones; tiered royalties up to the mid-twenties%.
• Partnership expands senaparib’s licensed reach to 66 countries.
• European MAA was accepted by the EMA in August 2025; approval expected in H2 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Impact Therapeutics Inc. published the original content used to generate this news brief via IIS, the regulatory disclosure system operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260730-12262310), on July 30, 2026, and is solely responsible for the information contained therein.